8-K/A: Becton Dickinson Appoints Vitor Roque as CFO

Becton, Dickinson and Company announces the permanent appointment of Vitor Roque as Executive Vice President and Chief Financial Officer, effective May 7, 2026, following his tenure as interim CFO.

Summary

• Vitor Roque has been officially appointed as the Executive Vice President and Chief Financial Officer (CFO) of Becton, Dickinson and Company (BD), effective May 7, 2026.
• Roque has been serving as the interim CFO since December 2025.
• His compensation package includes an annual base salary of $770,000, an annual target bonus of 95% of his base salary, and an annual equity compensation award target value of $3,000,000.
• Additionally, he received a $250,000 cash payment and a $250,000 time-vested unit grant in recognition of his interim service.
• Roque has over 25 years of experience at BD, holding various senior finance and operations roles.
• He played a key role in advancing BD's 'New BD' strategy, including the early completion of the Biosciences & Diagnostic Solutions business separation.
• The company highlighted Roque's deep understanding of the business, proven ability to translate strategy into performance, and discipline in execution.
• Roque will also have a two-year employment agreement post-change of control, with a severance multiple of two times salary and bonus.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, reflecting leadership stability and confidence in an experienced internal candidate to drive future growth and value creation.

Positives

• Permanent appointment of Vitor Roque as CFO, indicating leadership stability.
• Roque's compensation package reflects his senior role and includes significant equity and bonus potential.
• Roque's extensive experience (over 25 years) and deep understanding of BD's business are seen as strong assets.
• Successful completion of the Biosciences & Diagnostic Solutions business separation ahead of schedule under Roque's interim leadership.
• CEO Tom Polen expresses confidence in Roque's ability to drive growth and create long-term shareholder value.
• Roque's global perspective and execution experience are expected to enhance financial discipline and organizational speed.

Negatives

• No explicit negative financial results or operational setbacks are mentioned in relation to this appointment.
• The filing is an amendment to a previous 8-K, suggesting a procedural update rather than new operational information.

Risks

• The filing does not explicitly detail new risks associated with this executive appointment.
• Standard executive employment risks, such as continued performance and retention, are implicitly present.

Future Outlook

The company, under Vitor Roque's financial leadership, is focused on accelerating progress, unlocking significant growth, increasing impact on global healthcare, driving consistent performance, delivering durable growth, and increasing shareholder value creation.

Management Comments

• "Following a comprehensive search process, it was clear that Vitor is the right leader to serve as BDs next CFO, reflecting both his capabilities and the strength of our leadership pipeline," said Tom Polen, chairman and CEO of BD.
• "Vitor brings an unmatched understanding of our business, a proven ability to translate strategy into performance and the discipline to drive consistent execution at scale."
• "He has been an important leader in advancing our transformation and strengthening financial performance, and I'm confident he will help us deliver the next phase of growth and create long-term value for our shareholders and customers."
• "This is an important moment for BD, and I'm honored to step into this role as we accelerate on our progress," said Vitor Roque.
• "After more than two decades with the company, I see tremendous opportunity ahead - with a clear, welldefined strategy to unlock significant growth and increase our impact on global healthcare."
• "With a strong operating foundation, disciplined financial management, and focused execution, BD is well positioned to drive consistent performance, deliver durable growth and increase shareholder value creation as we continue to deliver on our purpose of advancing the world of health."

Industry Context

StockSavvy.ai notes that the appointment of a seasoned internal executive like Vitor Roque to the CFO role is a common strategy in the medical technology sector, often signaling a commitment to continuity and leveraging deep institutional knowledge to execute strategic initiatives.

Management Changes

Related Party Transactions

• Mr. Roque does not have any family relationships with any of the Company's directors or executive officers.
• There are no arrangements or understandings between Mr. Roque and any other persons pursuant to which he was selected as an officer.
• There are no transactions between Mr. Roque and the Company that would be required to be reported under Item 404(a) of Regulation S-K.

Stakeholder Impact

• Shareholders: Expected to benefit from continued financial discipline, growth, and value creation under experienced leadership.
• Employees: The appointment reinforces leadership stability and may signal continued focus on strategic execution.
• Customers: Indirectly benefit from improved operational efficiency and innovation driven by strong financial management.
• Creditors: Benefit from the company's commitment to financial discipline and consistent performance.

Next Steps

• Continue to execute on the 'New BD' strategy.
• Drive consistent performance and durable growth.
• Increase shareholder value creation.
• Advance the company's purpose of advancing the world of health.

Key Dates

Recommendation

The filing is an amendment to an 8-K detailing an executive appointment and compensation. While positive in terms of leadership stability and confidence in an internal candidate, it does not introduce new material financial performance data or strategic shifts that would warrant a change in recommendation based solely on this document.

Keywords

Becton Dickinson, Vitor Roque, Chief Financial Officer, CFO Appointment, Executive Appointment, Medical Technology, Financial Leadership, SEC Filing